{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:50:56Z","timestamp":1787017856320,"version":"build-2736575974"},"reference-count":1,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[1999]]},"abstract":"<jats:p>The state-of-the art therapy of cutaneous T cell lymphoma (CTCL) is reviewed. Commonly used treatments for early-stage (patch\/plaque) mycosis fungoides (MF) include topical corticosteroids, mechlorethamine, carmustine, ultraviolet light B and PUVA. Total skin electron beam (TSEB) therapy is indicated for widespread infiltrated plaque and tumor stage disease. Low-dose methotrexate is often useful for resistant patch\/plaque MF and erythrodermic CTCL. Interferon \u03b1 (IFN-\u03b1) is indicated for methotrexate failures and recurrent tumors following TSEB therapy. Photopheresis may be helpful for early-stage erythrodermic CTCL but is very costly. Retinoids may be of value for early and moderately advanced CTCL particularly in combination with other agents such as IFN-\u03b1 and PUVA. Systemic disease usually requires combination chemotherapy such as that used for non-Hodgkin\u2019s lymphoma; however, responses are usually short lived.<\/jats:p>","DOI":"10.1159\/000018214","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T13:25:18Z","timestamp":1050413118000},"page":"102-105","source":"Crossref","is-referenced-by-count":51,"title":["Cutaneous T Cell Lymphoma: Update of Treatment"],"prefix":"10.1159","volume":"199","author":[{"given":"H.S.","family":"Zackheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[1999,10,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.8.949"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/18214","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/18214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:56:28Z","timestamp":1745456188000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000018214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999]]},"references-count":1,"journal-issue":{"issue":"2","published-online":{"date-parts":[[1999,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000018214","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999]]}}}